



November 11, 2020

Initiatives Against COVID-19 in Canada - Phase 1 Results for COVID-19 Vaccine Candidate -

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno) announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; CEO; Bruce D. Clark) has announced the positive results of the Phase 1 clinical trial of its plant-derived virus-like particle (VLP) vaccine (project code:MT-2766) for the prevention of coronavirus disease 2019 (COVID-19) which has been developed by Medicago.

The summary of the Phase 1 clinical study and results are as follows:

- **Subjects:** 180 healthy Canadian subjects, male and female aged 18-55.
- **Dosage and administration:** Evaluated dosages of 3.75, 7.5 or 15 µg of the VLP vaccine candidate alone or with each of the two adjuvants – GSK’s adjuvant and Dynavax’s adjuvant after two doses.
- **Endpoints:** Safety and immunogenicity.
- **Results:** Induced robust neutralizing antibody and cellular immune response in the adjuvant group. No severe adverse events were observed.

Based on the overall data profile, Medicago plans to proceed with the Phase 2/3 clinical trial, subject to regulatory approval.

Mitsubishi Tanabe Pharma Group will work to develop and deliver MT-2766 to society as soon as possible, contributing even further to the prevention of COVID-19, a pressing social issue.

Medicago release (November 10, 2020, local time)

Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119